<DOC>
	<DOC>NCT00815659</DOC>
	<brief_summary>The primary objective is to evaluate the efficacy of rosuvastatin therapy on plasma lipid profile (Low Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), total cholesterol, triglyceride) in patients with metabolic syndrome.</brief_summary>
	<brief_title>Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>metabolic syndrome (according to National Cholesterol Education Program (NCEP) Adenosine triphosphate (ATP) Ill criteria) LDLCholesterol &gt; 130mg/dl HDLCholesterol &lt; 40mg/dl in males and &lt;50mg/dl in females Triglycerides &lt; 400 mg/dl With a concomitant coronary disease Currently under statin therapy or previously treated with statins within the last 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>plasma lipid profile</keyword>
	<keyword>metabolic syndrome</keyword>
</DOC>